Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Hepatol ; 18(6): 841-848, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31611065

RESUMO

INTRODUCTION AND OBJECTIVES: Limited data describe current SBP epidemiology and specific secondary SBP prophylactic regimens, leading to variable prescribing practices. This work aims to compare 90-day and one-year SBP recurrence and mortality based on secondary SBP antibiotic prophylaxis regimens. MATERIALS AND METHODS: We performed a retrospective cohort of patients >18 years with an SBP diagnosis from 2010 to 2015 at two academic institutions. Eligible patients had ascitic PMN counts ≥250cells/mm3 or a positive ascitic culture. Patients were compared based on secondary SBP prophylaxis regimens (i.e., daily, intermittent, or no prophylaxis). RESULTS: Of 791 patients with ascitic fluid samples, 86 patients were included. Antibiotic prophylaxis included daily (n=34), intermittent (n=36), or no prophylaxis (n=16). Nearly half of SBP episodes had a positive ascitic fluid culture; 50% were gram-negative pathogens, and 50% were gram-positive pathogens. Daily and intermittent regimens had similar rates of recurrence at 90-days (19.4% vs. 14.7%, p=0.60) and one-year (33.3% vs. 26.5%, p=0.53). Similarly, mortality did not differ among daily and intermittent regimens at 90-days (32.4% vs. 30.6%, p=0.87) or one-year (67.6% vs. 63.9%, p=0.74). When comparing any prophylaxis vs. no prophylaxis, there were no differences in 90-day or one-year recurrence or mortality. CONCLUSIONS: In patients with a history of SBP, our data indicate similar outcomes with daily, intermittent, or no secondary antibiotic prophylaxis. With available data, including ours, demonstrating a changing epidemiology for SBP pathogens, further data is required to determine if traditional approaches to secondary SBP prophylaxis remain appropriate.


Assuntos
Antibacterianos/administração & dosagem , Infecções Bacterianas/prevenção & controle , Peritonite/prevenção & controle , Idoso , Ascite/etiologia , Líquido Ascítico , Infecções Bacterianas/etiologia , Infecções Bacterianas/mortalidade , Estudos de Casos e Controles , Ceftizoxima/administração & dosagem , Ceftizoxima/análogos & derivados , Quimioprevenção/métodos , Ciprofloxacina/administração & dosagem , Estudos de Coortes , Feminino , Humanos , Estimativa de Kaplan-Meier , Cirrose Hepática/complicações , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Moxifloxacina/administração & dosagem , Análise Multivariada , Peritonite/etiologia , Peritonite/mortalidade , Modelos de Riscos Proporcionais , Recidiva , Estudos Retrospectivos , Combinação Trimetoprima e Sulfametoxazol/administração & dosagem , Cefpodoxima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA